Results 1 to 10 of about 34,485 (247)

Phosphocholine-Modified Lipooligosaccharides of Haemophilus influenzae Inhibit ATP-Induced IL-1β Release by Pulmonary Epithelial Cells [PDF]

open access: yesMolecules, 2018
Phosphocholine-modified bacterial cell wall components are virulence factors enabling immune evasion and permanent colonization of the mammalian host, by mechanisms that are poorly understood.
Katrin Richter   +11 more
doaj   +3 more sources

New Therapeutic Approaches for the Treatment of Rheumatoid Arthritis may Rise from the Cholinergic Anti-Inflammatory Pathway and Antinociceptive Pathway [PDF]

open access: yesThe Scientific World Journal, 2010
Due to the complex etiology of rheumatoid arthritis (RA), it is difficult to be completely cured at the current stage although many approaches have been applied in clinics, especially the wide application of nonsteroidal anti-inflammatory drugs (NSAIDs ...
Xiao Hua Pan   +5 more
doaj   +2 more sources

Cholinergic network modulation in disinhibited eating behavior [PDF]

open access: yesCommunications Biology
Cholinergic modulation of brain reward circuitry appears to play a crucial role in information processing about salience as a key biological mechanism in obesity. However, changes in acetylcholine transmission leading to abnormal eating behavior have not
Swen Hesse   +17 more
doaj   +2 more sources

The Novel, Nicotinic Alpha7 Receptor Partial Agonist, BMS-933043, Improves Cognition and Sensory Processing in Preclinical Models of Schizophrenia. [PDF]

open access: goldPLoS ONE, 2016
The development of alpha7 nicotinic acetylcholine receptor agonists is considered a promising approach for the treatment of cognitive symptoms in schizophrenia patients. In the present studies we characterized the novel agent, (2R)-N-(6-(1H-imidazol-1-yl)
Linda J Bristow   +22 more
doaj   +3 more sources

Molecular insights into the α6β4 nicotinic acetylcholine receptor function and ligand recognition [PDF]

open access: yesNature Communications
The α6β4 nicotinic acetylcholine receptor (nAChR) is found in the sensory neurons of dorsal root ganglia. It is a promising therapeutic target for pain.
Jiawei Su   +10 more
doaj   +2 more sources

Fluorescence activation mechanism and imaging of drug permeation with new sensors for smoking-cessation ligands

open access: yeseLife, 2022
Nicotinic partial agonists provide an accepted aid for smoking cessation and thus contribute to decreasing tobacco-related disease. Improved drugs constitute a continued area of study. However, there remains no reductionist method to examine the cellular
Aaron L Nichols   +18 more
doaj   +1 more source

Nicotinic acetylcholine receptor agonists attenuate septic acute kidney injury in mice by suppressing inflammation and proteasome activity. [PDF]

open access: yesPLoS ONE, 2012
Sepsis is one of the leading causes of acute kidney injury (AKI). Septic patients who develop acute kidney injury (AKI) are at increased risk of death. To date there is no effective treatment for AKI or septic AKI.
Prodyot K Chatterjee   +6 more
doaj   +1 more source

Acute activation, desensitization and smoldering activation of human acetylcholine receptors. [PDF]

open access: yesPLoS ONE, 2013
The behavioral effects of nicotine and other nicotinic agonists are mediated by AChRs in the brain. The relative contribution of acute activation versus chronic desensitization of AChRs is unknown. Sustained "smoldering activation" occurs over a range of
Barbara G Campling   +2 more
doaj   +1 more source

Silent agonists for α7 nicotinic acetylcholine receptors

open access: yesPharmacological Research, 2023
We discuss models for the activation and desensitization of α7 nicotinic acetylcholine receptors (nAChRs) and the effects of efficacious type II positive allosteric modulators (PAMs) that destabilize α7 desensitized states.
Roger L. Papke   +2 more
doaj   +1 more source

Recent Advances in the Discovery of Nicotinic Acetylcholine Receptor Allosteric Modulators

open access: yesMolecules, 2023
Positive allosteric modulators (PAMs), negative allosteric modulators (NAMs), silent agonists, allosteric activating PAMs and neutral or silent allosteric modulators are compounds capable of modulating the nicotinic receptor by interacting at allosteric ...
Dina Manetti   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy